{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:34:15Z","timestamp":1765280055711,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.cllc.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T21:57:34Z","timestamp":1533160654000},"page":"461-463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin\u2019"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-5076","authenticated-orcid":false,"given":"Paolo","family":"Bironzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio Vittorio","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.07.007_bib1","first-page":"1116","article-title":"LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2018.07.007_bib2","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non\u2013small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.cllc.2018.07.007_bib3","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non\u2013small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2018.07.007_bib4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.07.007_bib5","first-page":"3235","article-title":"Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514","volume":"18","author":"Worzalla","year":"1998","journal-title":"Anticancer Res"},{"issue":"suppl 4","key":"10.1016\/j.cllc.2018.07.007_bib6","article-title":"MTA (LY231514): relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity","volume":"9","author":"Niyikiza","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2018.07.007_bib7","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vozelgang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.07.007_bib8","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"author":"US Food and Drug Administration","key":"10.1016\/j.cllc.2018.07.007_bib9"},{"key":"10.1016\/j.cllc.2018.07.007_bib10","first-page":"147","article-title":"Studies on vitamin B12 absorption patterns in normal subjects following oral and intramuscolar administration of vitamin B12","volume":"11","author":"Dixit","year":"1957","journal-title":"Indian J Med Sci"},{"key":"10.1016\/j.cllc.2018.07.007_bib11","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1634\/theoncologist.2014-0221","article-title":"A\u00a0prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non\u2013small cell lung cancer","volume":"19","author":"Takagi","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2018.07.007_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2018.05.017","article-title":"Safety of same-day vitamin B12 supplementation in patients receiving pemetrexed for the treatment of non\u2013small-cell lung cancer or pleural mesothelioma: a retrospective analysis","author":"Schlei","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2018.07.007_bib13","doi-asserted-by":"crossref","unstructured":"Singh N, Baldi M, Kaur J, Prasad K, Kapoor R, Behera D. Timing of B12\/folate supplementation in NSCLC patients on pemetrexed based chemotherapy: final results of PEMVITASTART randomized trial [abstract MA 03.02]. Paper presented at: 18th World Conference on Lung Cancer; Yokohama, Japan; October\u00a02017.","DOI":"10.1093\/annonc\/mdx671.006"},{"key":"10.1016\/j.cllc.2018.07.007_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti\u2013PD-1 and anti\u2013CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2018.07.007_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.07.007_bib16","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.07.007_bib17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1 positive, advanced non\u2013small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2018.07.007_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non\u2013small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2018.07.007_bib19","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1 positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.07.007_bib20","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.cllc.2018.07.007_bib21","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1017\/S0007114507832971","article-title":"Selected vitamins and trace elements support immune function by strenghtening epithelial barriers and cellular and humoral immune responses","volume":"98","author":"Maggini","year":"2007","journal-title":"Br J Nutr"},{"key":"10.1016\/j.cllc.2018.07.007_bib22","first-page":"43","article-title":"Folate status and the immune system","volume":"15","author":"Dhur","year":"1991","journal-title":"Prog Food Nutr Sci"},{"key":"10.1016\/j.cllc.2018.07.007_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1046\/j.1365-2249.1999.00870.x","article-title":"Immunomodulation by vitamin B12: augmentation of CD8+ T lymphocytes and natural killer (NK) cell activity in vitamin B12\u2013deficient patients by methyl-B12 treatment","volume":"116","author":"Tamura","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cllc.2018.07.007_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418301918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418301918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:07:49Z","timestamp":1761505669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730418301918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1525730418301918"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.07.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin\u2019","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.05.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}